- Home
- INSG vs KLRS Comparison
INSG vs KLRS Comparison
Compare INSG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSG
- KLRS
- Stock Information
- Founded
- INSG 1996
- KLRS 2019
- Country
- INSG United States
- KLRS United States
- Employees
- INSG N/A
- KLRS N/A
- Industry
- INSG Telecommunications Equipment
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSG Telecommunications
- KLRS Health Care
- Exchange
- INSG Nasdaq
- KLRS Nasdaq
- Market Cap
- INSG 110.6M
- KLRS 129.0M
- IPO Year
- INSG 2000
- KLRS N/A
- Fundamental
- Price
- INSG $6.40
- KLRS $2.69
- Analyst Decision
- INSG Buy
- KLRS Buy
- Analyst Count
- INSG 3
- KLRS 1
- Target Price
- INSG $13.00
- KLRS N/A
- AVG Volume (30 Days)
- INSG 126.5K
- KLRS 57.0K
- Earning Date
- INSG 08-07-2025
- KLRS 08-15-2025
- Dividend Yield
- INSG N/A
- KLRS N/A
- EPS Growth
- INSG N/A
- KLRS N/A
- EPS
- INSG 0.31
- KLRS N/A
- Revenue
- INSG $185,412,000.00
- KLRS N/A
- Revenue This Year
- INSG N/A
- KLRS N/A
- Revenue Next Year
- INSG $14.39
- KLRS N/A
- P/E Ratio
- INSG $23.35
- KLRS N/A
- Revenue Growth
- INSG 20.40
- KLRS N/A
- 52 Week Low
- INSG $6.24
- KLRS $2.28
- 52 Week High
- INSG $20.67
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- INSG 28.80
- KLRS N/A
- Support Level
- INSG $7.19
- KLRS N/A
- Resistance Level
- INSG $7.58
- KLRS N/A
- Average True Range (ATR)
- INSG 0.36
- KLRS 0.00
- MACD
- INSG -0.11
- KLRS 0.00
- Stochastic Oscillator
- INSG 7.79
- KLRS 0.00
About INSG Inseego Corp.
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.